Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Neoplasms, Plasma Cell 1Mesothelioma, Malignant 1Carcinoma, Non-Small-Cell Lung 1Advanced or Metastatic Solid Tumors 1Advanced Breast Cancer 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 25Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × Combined Modality Therapy × Clear all
NCT01889420 2015-07-31

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

New Mexico Cancer Research Alliance

Phase 1 Terminated
1 enrolled 3 charts
Plasma cell

Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡